Trials / Recruiting
RecruitingNCT06756308
A Study of Enasidenib in People With T-Cell Lymphoma
A Phase 2 Study of Enasidenib in IDH2-Mutant Angioimmunoblastic T-Cell Lymphoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The researchers are doing this study to find out whether enasidenib is a safe treatment for people with angioimmunoblastic T-cell lymphoma (AITL) that has an IDH2 mutation. The researchers will look at the safety of enasidenib when it is given alone or in combination with the drug rituximab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enasidenib | Enasidenib 100 mg daily on 28-day cycles. |
| DRUG | Rituximab | IV rituximab 375 mg/m² weekly for the first month, and monthly thereafter on 28-day cycles, for a total of four months of rituximab. |
Timeline
- Start date
- 2024-12-24
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
- First posted
- 2025-01-02
- Last updated
- 2026-04-07
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06756308. Inclusion in this directory is not an endorsement.